Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo

Abstract We aimed to identify potent biliverdin reductase (BVRA) inhibitors as a novel concept for the treatment of severe unconjugated hyperbilirubinemia. 1280 FDA-approved compounds were screened in vitro for their ability to inhibit human and rat BVRA activity and 26 compounds were identified a...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Remco van Dijk, Sem J. Aronson, Dirk R. de Waart, Stan F. van de Graaf, Suzanne Duijst, Jurgen Seppen, Ronald Oude Elferink, Ulrich Beuers, Piter J. Bosma
Format: article
Langue:EN
Publié: Nature Portfolio 2017
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/d12f4548a8564f6a914ed21b89937903
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!